First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Neeta Pandit-Taskar; Michael A. Postow; Matthew D. Hellmann; James J. Harding; Christopher A. Barker; Joseph A. O’Donoghue; Martha Ziolkowska; Shutian Ruan; Serge K. Lyashchenko; Frank Tsai; Michael Farwell; Tara C. Mitchell; Ron Korn; William Le; Jason S. Lewis; Wolfgang A. Weber; Deepak Behera; Ian Wilson; Michael Gordon; Anna M. Wu; Jedd D. Wolchok

doi:10.2967/jnumed.119.229781

Research ArticleOncology

First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Neeta Pandit-Taskar, Michael A. Postow, Matthew D. Hellmann, James J. Harding, Christopher A. Barker, Joseph A. O’Donoghue, Martha Ziolkowska, Shutian Ruan, Serge K. Lyashchenko, Frank Tsai, Michael Farwell, Tara C. Mitchell, Ron Korn, William Le, Jason S. Lewis, Wolfgang A. Weber, Deepak Behera, Ian Wilson, Michael Gordon, Anna M. Wu and Jedd D. Wolchok

Journal of Nuclear Medicine April 2020, 61 (4) 512-519; DOI: https://doi.org/10.2967/jnumed.119.229781

Neeta Pandit-Taskar

1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

2Department of Radiology, Weill Cornell Medical College, New York, New York

3Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael A. Postow

4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

5Department of Medicine, Weill Cornell Medical College, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthew D. Hellmann

3Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York

4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

5Department of Medicine, Weill Cornell Medical College, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

James J. Harding

4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

5Department of Medicine, Weill Cornell Medical College, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christopher A. Barker

6Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Joseph A. O’Donoghue

7Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martha Ziolkowska

1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shutian Ruan

1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

2Department of Radiology, Weill Cornell Medical College, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Serge K. Lyashchenko

8Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York

9Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Frank Tsai

10Honor Health, Scottsdale, Arizona

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Farwell

11University of Pennsylvania, Philadelphia, Pennsylvania

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tara C. Mitchell

11University of Pennsylvania, Philadelphia, Pennsylvania

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ron Korn

12Imaging Endpoints, Scottsdale, Arizona

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

William Le

13ImaginAb, Inc., Inglewood, California; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jason S. Lewis

1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

8Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York

9Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wolfgang A. Weber

1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Deepak Behera

13ImaginAb, Inc., Inglewood, California; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ian Wilson

13ImaginAb, Inc., Inglewood, California; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Gordon

10Honor Health, Scottsdale, Arizona

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anna M. Wu

13ImaginAb, Inc., Inglewood, California; and

14Department of Molecular Imaging and Therapy, Beckman Research Institute of the City of Hope, Duarte, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jedd D. Wolchok

5Department of Medicine, Weill Cornell Medical College, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 61, Issue 4

April 1, 2020

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Journal of Nuclear Medicine Apr 2020, 61 (4) 512-519; DOI: 10.2967/jnumed.119.229781

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Journal of Nuclear Medicine Apr 2020, 61 (4) 512-519; DOI: 10.2967/jnumed.119.229781

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
Quo Vadis, Molecular Imaging?
Can Molecular Imaging Measure T-cell Activation?
The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment

Google Scholar

Oncology

First Experience Using ¹⁸F-Flubrobenguane PET Imaging in Patients with Suspected Pheochromocytoma or Paraganglioma
Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating ESR1 Mutation
Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial

Show more Oncology

Translational

First Experience Using ¹⁸F-Flubrobenguane PET Imaging in Patients with Suspected Pheochromocytoma or Paraganglioma
First-in-Human Evaluation of ¹⁸F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A
First-in-Humans Study of ⁶⁸Ga-DOTA-Siglec-9, a PET Ligand Targeting Vascular Adhesion Protein 1

Show more Translational

Keywords

89Zr-IAB22M2C PET
minibody
CD8+ T cell
lung cancer
Melanoma

Main menu

User menu

Search

First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Oncology

Translational

Similar Articles

Keywords